Loading clinical trials...
Loading clinical trials...
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), L...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sarepta Therapeutics, Inc.
NCT00390104 · Neuromuscular; Disorder, Hereditary, Duchenne/Becker Muscular Dystrophy, and more
NCT01403402 · Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), and more
NCT03652259 · Limb-Girdle Muscular Dystrophy, Type 2E
NCT06399770 · Limb-girdle Muscular Dystrophy
Barrow Neurological Institute
Phoenix, Arizona
Arkansas Children's
Little Rock, Arkansas
University of California San Diego
La Jolla, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions